Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 7/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.43 |
| ▸ | RARB | P10826 | 6/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553579 | 0.92 | SLC16A3 (0.46) | PLK1PLK3SLC16A3RARBMEN1 | |
| SCHEMBL3555276 | 0.88 | SLC16A3 (0.47) | PLK1PLK3SLC16A3RARBEP300 | |
| SCHEMBL3556564 | 0.87 | SLC16A3 (0.47) | PLK1PLK3SLC16A3RARBMEN1 | |
| SCHEMBL3563442 | 0.87 | SLC16A3 (0.44) | PLK1PLK3SLC16A3RARBEP300 | |
| SCHEMBL3558209 | 0.87 | SLC16A3 (0.44) | PLK1PLK3SLC16A3RARBMEN1 | |
| SCHEMBL3557951 | 0.86 | SLC16A3 (0.48) | PLK1PLK3SLC16A3RARBEP300 | |
| SCHEMBL3553932 | 0.84 | SLC16A3 (0.46) | PLK1PLK3SLC16A3RARBEP300 | |
| SCHEMBL3554954 | 0.84 | SLC16A3 (0.54) | PLK1PLK3SLC16A3RARBMEN1 | |
| SCHEMBL3552964 | 0.84 | SLC16A3 (0.46) | PLK1PLK3SLC16A3RARBMEN1 | |
| SCHEMBL3561330 | 0.82 | SLC16A3 (0.42) | PLK1PLK3SLC16A3RARBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | PLK1 4876/4885PLK3 3999/4885SLC16A3 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.